{
    "clinical_study": {
        "@rank": "104343", 
        "acronym": "OSKIRA 4 SS", 
        "arm_group": [
            {
                "arm_group_label": "Dosing Group A", 
                "arm_group_type": "Experimental", 
                "description": "Oral treatment and subcutaneous injection"
            }, 
            {
                "arm_group_label": "Dosing Group D", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral treatment and subcutaneous injection"
            }, 
            {
                "arm_group_label": "Dosing Group E", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative\n      and more sensitive modalities for measuring the beneficial effects of syk inhibition with\n      fostamatinib in patients with active RA. This MRI sub-study was reported later than the main\n      study due to recruitment delays at specialist imaging sites and so is registered and\n      presented entirely separately to the main study results.\n\n      This study will investigate the impact of treatment on joint activity and damage by\n      assessing synovitis, osteitis, bone erosions and joint space narrowing."
        }, 
        "brief_title": "Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Sub-study to OSKIRA-4: A Phase IIB, Multi-Centre, Randomised, Double-Blind,\n      Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium\n      Monotherapy Compared with Placebo or Adalimumab Monotherapy in Patients with Active\n      Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study Date: 21 March 2011 Version: 1\n      Primary objective: Assess the efficacy of fostamatinib in reducing joint synovial disease\n      activity as measured by: - Change from baseline to Week 6 (versus placebo) in OMERACT RAMRIS\n      synovitis score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: - Male or female aged 18 and over - Active rheumatoid arthritis (RA)\n        diagnosed after the age of 16 and diagnosis within 5 years prior to study visit 1 and\n        inadequate response to treatment with a maximum 2 Disease-Modifying anti-rheumatic drug\n        (DMARD) therapies, or diagnosis within 5 years prior to study visit 1 and intolerance to\n        DMARD therapy, or diagnosis within 2 years prior to study visit 1 and no previous use of\n        DMARDs - 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint\n        count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or\n        C-Reactive Protein (CRP) blood result of 10mg/L or more - At least 2 of the following:\n        documented history or current presence of positive rheumatoid factor (blood test),\n        radiographic erosion within 12 months prior to study enrolment, presence of serum\n        anti-cyclic citrullinated peptide antibodies (blood test) Presence of at least one swollen\n        hand or wrist joint. Presence of synovitis on baseline MRI scan, defined as at least 1\n        joint with RAMRIS synovitis score of +1 or greater.  Exclusion Criteria: - Females who are\n        pregnant or breast feeding - Poorly controlled hypertension - Liver disease or significant\n        liver function test abnormalities - Certain inflammatory conditions (other than rheumatoid\n        arthritis), connective tissue diseases or chronic pain disorders - Recent or significant\n        cardiovascular disease - Significant active or recent infection including tuberculosis -\n        Previously received treatment with a TNF alpha antagonist (including etanercept,\n        certolizumab, adalimumab, infliximab, golimumab) or anakinra or previous treatment with\n        other biological agent including rituximab, abatacept and tocilizumab - Use of any DMARDs\n        within 6 weeks before first study visit - Severe renal impairment - Neutropenia Unable to\n        undergo an MRI examination (e.g. presence of a pacemaker, defibrillator, or other\n        implanted metallic device such as anterior interbody cages, aneurysm clip or pedicle\n        screws). Known allergy to Gadolinium-based contrast agent,  tattoos [in area of\n        examination if contains metallic pigment], Likely to require sedation for the procedure.\n        eGFR less than 55 mL/min"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "198", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092961", 
            "org_study_id": "D4300C00004Sub"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dosing Group A", 
                "description": "Fostamatinib 100mg twice daily and placebo injection once every two weeks", 
                "intervention_name": "Fostamatinib plus placebo injections", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dosing Group D", 
                "description": "Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks, plus placebo to fostamatinib twice daily.", 
                "intervention_name": "Adalimumab and placebo of fostamatinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dosing Group E", 
                "description": "Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.", 
                "intervention_name": "Placebo of fostamatinib, fostamatinib, and placebo injections", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "OSKIRA", 
            "fostamatinib", 
            "CE-MRI", 
            "DCE-MRI"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Glendale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paradise Valley", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pleven", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mississauga", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Balatonf\u00fcred", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stellenbosch", 
                        "country": "South Africa"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Bulgaria", 
                "Canada", 
                "Czech Republic", 
                "Germany", 
                "Hungary", 
                "Netherlands", 
                "Poland", 
                "Russian Federation", 
                "South Africa", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Placebo or Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study", 
        "overall_official": {
            "affiliation": "AstraZeneca", 
            "last_name": "Neil MacKillop, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Public Health Institute", 
                "Slovakia: State Institute for Drug Control", 
                "South Africa: Medicines Control Council", 
                "Ukraine: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) synovitis score using Contrast-Enhanced MRI (CE-MRI)", 
            "measure": "OMERACT RAMRIS synovitis score at week 6", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) synovitis score using Contrast-Enhanced MRI (CE-MRI)", 
                "measure": "OMERACT RAMRIS synovitis score at week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 Weeks"
            }, 
            {
                "description": "Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) osteitis score using Contrast-Enhanced MRI (CE-MRI)", 
                "measure": "OMERACT RAMRIS osteitis score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 Weeks and 24 Weeks"
            }, 
            {
                "description": "Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) erosion score using Contrast-Enhanced MRI (CE-MRI)", 
                "measure": "Prevention of structural joint damage as measured by OMERACT RAMRIS erosion score and joint space narrowing", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 Weeks and 24 Weeks"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to\n    Rigel Pharmaceuticals."
    }
}